The clinical and immunological features of leprosy

British Medical Bulletin

Volumn 77-78, Issue 1, 2006, Pages 103-121

  Walker, S L ^a   Lockwood, D N J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Immunology; Leprosy; Reactions; Treatment

Indexed keywords

CHLOROQUINE; CLARITHROMYCIN; CLOFAZIMINE; COLCHICINE; CORTICOSTEROID; DAPSONE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; LYMPHOTOXIN; MINOCYCLINE; OFLOXACIN; OXYGEN RADICAL; PEFLOXACIN; PENTOXIFYLLINE; PREDNISOLONE; RIFAMPICIN; THALIDOMIDE; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL INFECTION; BLINDNESS; BODY FLUID DISCOLORATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL FEATURE; CONJUNCTIVAL DISCOLORATION; DELAYED HYPERSENSITIVITY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; ENTEROPATHY; ERYTHEMA NODOSUM LEPROSUM; GENETIC SUSCEPTIBILITY; HEMOLYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERSENSITIVITY REACTION; ICHTHYOSIS; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LAGOPHTHALMOS; LEPROMATOUS LEPROSY; LEPROSY; MULTIBACILLARY LEPROSY; MULTIPLE CYCLE TREATMENT; MYCOBACTERIUM LEPRAE; NERVE BIOPSY; NEURITIS; PATIENT EDUCATION; PAUCIBACILLARY LEPROSY; PERIPHERAL NERVE; PRIORITY JOURNAL; REVIEW; SKIN DARKENING; SKIN DISCOLORATION; SKIN INFLAMMATION; SYSTEMIC DISEASE; TUBERCULOID LEPROSY;

DIAGNOSIS, DIFFERENTIAL; DISABLED PERSONS; HUMANS; LEPROSTATIC AGENTS; LEPROSY; PATIENT EDUCATION;

EID: 33846254946     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldl010     Document Type: Review

References (73)

1. Lockwood DNJ. Leprosy. In: Burns DA, Breathnach SM, Cox NH, Griffiths CEM (eds). Rook's Textbook of Dermatology, 7th edn, Vol. 2. Oxford: Blackwell Publishing, 2004,29.1-29.21.
2. Britton WJ, Lockwood DNJ. Leprosy. Lancet 2004;363:1209-19.
3. Global leprosy situation, 2005. Wkly Epidemiol Rec 2005;80:289-95.
4. Desikan KV, Sreevasta. Extended studies on the viability of Mycobacterium leprae outside the human body. Lepr Rev 1995;66:287-95.
5. Hatta M, van Beers SM, Madjid B et al. Distribution and persistence of Mycobacterium leprae nasal carriage among a population in which leprosy is endemic in Indonesia. Trans R Soc Trop Med Hyg 1995;89:381-5.
6. Hansen GHA. Undersogelser angaende spedalskhedens aasager. Norsk Magazin for Laegervidenskaben 1874;4(Suppl.):1-88.
7. Cole ST, Eiglmeier K, Parkhill J et al. Massive gene decay in the leprosy bacillus. Nature 2001;409:1007-11.
8. Ridley DS, Jopling WH. Classification of leprosy according to immunity. Int J Lepr 1966;34:255-73.
9. www.who.int/lep/disease/Eliminate_Leprosy_V8.pdf.
10. Chakravartti MR, Vogel F. A twin study on leprosy. Top Hum Genet 1973;1:1-123.
11. Mira MT, Alcaïs A, Thuc NV et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 2004;427:636-40.
12. Ciechanover A. The ubiquitin proteolytic system. Neurology 2006;66(Suppl. 1):1-13.
13. Roy S, Frodsham A, Saha B et al. Association of vitamin D receptor genotype with leprosy type. J Infect Dis 1999;179:187-91.
14. Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770-3.
15. Roy S, McGuire W, Mascie-Taylor CG et al. Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis 1997;176:530-2.
16. Santos AR, Suffys PN, Vanderborght PR et al. Role of tumor necrosis factor-alpha and interleukin-10 promoter gene polymorphisms in leprosy. J Infect Dis 2002;186:1687-91.
17. Fitness J, Floyd S, Warndorff DK et al. Large-scale candidate gene study of leprosy susceptibility in the Karonga district of northern Malawi. Am J Trop Med Hyg 2004;71:330-40.
18. Moraes MO, Pacheco AG, Schonkeren JJ et al. Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. Genes Immun 2004;5:592-5.
19. Malhotra D, Darvishi K, Sood S et al. IL-10 promoter single nucleotide polymorphisms are significantly associated with resistance to leprosy. Hum Genet 2005;118:295-300.
20. Modlin RL. Th1-Th2 paradigm: insights from leprosy. J Invest Dermatol 1994;102:828-32.
21. Brightbill HD, Libraty DH, Krutzik SR et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999;285:732-6.
22. Krutzik SR, Ochoa MT, Sieling PA et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med 2003;9:525-32.
23. Krutzik SR, Tan B, Li H et al. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat Med 2005;11:653-60.
24. Demangel C, Britton WJ. Interaction of dendritic cells with mycobacteria: where the action starts. Immunol Cell Biol 2000;78:318-24.
25. Texereau J, Chiche JD, Taylor W et al. The importance of Toll-like receptor 2 polymorphisms in severe infections. Clin Infect Dis 2005;41:S408-15.
26. Spellberg B, Edwards JE Jr. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 2001;32:76-102.
27. Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005;41(Suppl. 3): S189-93.
28. Modlin RL, Melancon-Kaplan J, Young SM et al. Learning from lesions: patterns of tissue inflammation in leprosy. Proc Natl Acad Sci USA 1988;85:1213-7.
29. Ochoa MT, Stenger S, Sieling PA et al. T-cell release of granulysin contributes to host defense in leprosy. Nat Med 2001;7:174-9.
30. Yamamura M, Uyemura K, Dens RJ et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991;254:277-9.
31. Libraty DH, Airan LE, Uyemura K et al. Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy. J Clin Invest 1997;99:336-41.
32. Job CK. Pathology of leprosy. In: Hastings RC (ed). Leprosy, 2nd edn. Edinburgh: Churchill Livingstone, 1994,193-234.
33. Lockwood DNJ, Colston MJ, Khanolkar-Young SR. The detection of Mycobacterium leprae protein and carbohydrate antigens in skin and nerve from leprosy patients with type 1 (reversal) reactions. Am J Trop Med Hyg 2002;66:409-15.
34. Oliveira RB, Ochoa MT, Sieling PA et al. Expression of Toll-Like Receptor 2 on human Schwann cells:a mechanism of nerve damage in leprosy. Infect Immun 2003;71:1427-33.
35. Khanolkar-Young S, Rayment N, Brickell PM et al. Tumour necrosis factor-alpha (TNF-α) synthesis is associated with skin and nerve pathology of leprosy reversal reactions. Clin Exp Immunol 1995;99:196-202.
36. Little D, Khanolkar-Young S, Coulthart A et al. Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun 2001;69:3413-7.
37. Kirkaldy A, Musonda AC, Khanolkar-Young S et al. Expression of CC and CXC chemokines and chemokine receptors in human leprosy skin lesions. Clin Exp Immunol 2003;134:447-53.
38. Andersson AK, Chaduvula MV, Atkinson SE et al. Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions. Infect Immun 2005;73:3725-33.
39. Simmons CP, Thwaites GE, Quyen NT et al. The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses. J Immunol 2005;175:579-90.
40. Sarno EN, Grau GE, Viera LM, Nery JA. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol 1991;84:103-8.
41. Barnes PF, Chatterjee D, Brennan PJ et al. Tumor necrosis factor production in patients with leprosy. Infect Immun 1992;60:1441-6.
42. Sampaio EP, Moraes MO, Nery JA et al. Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin Exp Immunol 1998;111:300-8.
43. Moreira AL, Kaplan G, Villahermosa LG et al. Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL. Int J Lepr Other Mycobact Dis 1998;66:61-5.
44. Haslett P, Roche P, Butlin CR et al. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. J Infect Dis 2005;192:2045-53.
45. Wolkenstein P, Latarjet J, Roujeau JC et al. Randomised comparison of versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-9.
46. Pfaltzgraff RE, Ramu G. Clinical leprosy. In: Hastings RC (ed). Leprosy, 2nd edn. Edinburgh: Churchill Livingstone, 1994,237-90.
47. Lockwood DNJ, Reid AJC. The diagnosis of leprosy is delayed in the United Kingdom. Q J Med 2001;94:207-12.
48. Pocaterra L, Jain S, Reddy R et al. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg 2006;74:868-79.
49. Ishikawa A, Ishikawa S, Hirakawa M. Osteoporosis, bone turnover and hypogonadism in elderly men with treated leprosy. Lepr Rev 2001;72:322-9.
50. Croft RP, Richardus JH, Nicholls PG, Smith WC. Nerve function impairment in leprosy: design, methodology, and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (The Bangladesh Acute Nerve Damage Study). Lepr Rev 1999;70:140-59.
51. van Brakel WH, Nicholls PG, Das L et al. The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lep Rev 2005;76:14-34.
52. van Brakel WH, Khawas IB. Silent neuropathy in leprosy: an epidemiological description. Lepr Rev 1994;65:350-60.
53. Ffytche TJ. The prevalence of disabling ocular complications of leprosy: a global study. Indian J Lepr 1998;70:49-59.
54. van Brakel WH, Khawas IB, Lucas SB. Reactions in leprosy: an epidemiological study of 386 patients in West Nepal. Lepr Rev 1994;65:190-203.
55. Manandhar R, LeMaster JW, Roche PW. Risk factors for erythema nodosum leprosum. Int J Lepr Other Mycobact Dis 1999;67:270-8.
56. Rijal A, Agrawal S, Agarwalla A, Lakhey M. Bullous erythema nodosum leprosum: a case report from Nepal. Lepr Rev 2004 ;75:177-80.
57. Lockwood DNJ, Sinha HH. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis 1999;67:6-12.
58. Ustianowski AP, Lawn SD, Lockwood DNJ. Interactions between HIV infection and leprosy: examining a paradox. Lancet Inf Dis 2006;6:350-60.
59. Schmiedel S, Ehrhardt S, Moll I, Burchard GD. A Thai patient with generalised inflammatory skin disease 18 years after migration to Europe. Lancet 2006;367:1458.
60. Ling TC, Prescott RJ, Daly M. Painful skin nodules and epididymo-orchitis. Arch Dermatol 2002;138:1607-12.
61. World Health Organisation. Chemotherapy of leprosy for control programmes. Technical Report Series 675. Geneva: WHO, 1982.
62. www.clinicalevidence.com.
63. Jopling WH. Complications of treatment with clofazimine (Lamprene: B663). Lepr Rev 1976;47:1-3.
64. Atkinson AJ Jr, Sheagren JN, Barba Rubio J, Knight V. Evaluation of B.663 in human leprosy. Int J Lepr Other Mycobact Dis 1967;35:119-27.
65. Degowin RL, Eppes RB, Powell RD, Carson PE.The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate- dehydrogenase deficiency. Bull World Health Organ 1966;35:165-79.
66. Simons JJ, Morales A. Minocycline and generalized cutaneous pigmentation. J Am Acad Dermatol 1980;33:244-7.
67. Croft RP, Nicholls PG, Steyerberg EW et al. A clinical prediction rule for nerve function impairment in leprosy patients-revisited after 5 years of follow-up. Lepr Rev 2003;74:35-41.
68. van Brakel WH, Khawas IB. Nerve function impairment in leprosy: a clinical and epidemiological study-Part 2. Results of steroid treatment. Lepr Rev 1996;67:104-18.
69. Rao PS, Sugaraman DST, Richard J, Smith WCS. Multi-centre, double-blind, randomized trial of three-steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev 2006;77:25-33.
70. Smith WC, Anderson AM, Withington SG et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). Br Med J 2004;328:1459.
71. WHO Expert Committee on Leprosy - Fifth Report. Technical Report Series 607. Geneva: World Health Organisation, 1977.
72. Cross H, Newcombe L. An intensive self care training programme reduces admissions for the treatment of plantar ulcers. Lepr Rev 2001;72:276-84.
73. Nicholls PG. Guidelines for social and economic rehabilitation. Lepr Rev 2000;71:422-65.